Trinity gains bioMerieux blood coagulation testing line
This article was originally published in The Gray Sheet
Executive Summary
Automated instruments and reagent menu for blood clotting parameter analysis composing bioMerieux's hemostasis product line are acquired by diagnostics firm Trinity Biotech May 25. Trinity will pay up to $51.9 mil., including $40 mil. at closing, with deferred payments of up to $11.9 mil. over two years. Combining the bioMerieux line with Trinity's existing coagulation testing products will add $40 mil. to Trinity's revenue next year and boost its share of the $600 mil. worldwide coagulation testing market from its current 5% level to an estimated 13%, the firm says. The market is growing at about 5% annually. The deal is in line with bioMerieux' focus on infectious diseases, cancer and cardiovascular diseases...